Open AccessErratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial
Author(s) -
Christoph Wanner,
Mark E. Cooper,
Odd Erik Johansen,
Robert D. Toto,
Julio Rosenstock,
Darren K. McGuire,
Steven E. Kahn,
Egon Pfarr,
Sven Schnaidt,
Maximilian von Eynatten,
Jyothis T. George,
Nicholas D. Gollop,
Nikolaus Marx,
John H. Alexander,
Bernard Zinman,
Vlado Perkovic
Publication year - 2021
Publication title -
clinical kidney journal
Language(s) - English
Resource type - Journals
eISSN - 2048-8513
pISSN - 2048-8505
DOI - 10.1093/ckj/sfab104
Subject(s) - linagliptin , medicine , proteinuria , type 2 diabetes , placebo , randomized controlled trial , diabetes mellitus , kidney , endocrinology , alternative medicine , pathology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom